Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Fibrinogen receptor occupancy, antiplatelet activity and safety of lefradafiban

Nov. 10, 1997

No Comments

Lamifiban efficacy demonstrated in PARAGON trial

Nov. 10, 1997

No Comments

Preclinical and clinical profile of Searle's fibrinogen antagonist

Nov. 10, 1997

No Comments

TP-9201 covered by new U.S. patent

Nov. 10, 1997

No Comments

Fibrinogen antagonists from Merck & Co.

Nov. 10, 1997

No Comments

Spotlight on thrombin inhibitors

Nov. 10, 1997

No Comments

ReoPro cleared in U.S. for expanded labeling

Nov. 7, 1997

No Comments

Saruplase efficacy demonstrated in large patient study

Nov. 7, 1997

No Comments

PEG-hirudin compared to established antithrombotic agents

Nov. 7, 1997

No Comments

Akzo Nobel prepares two series of thrombin inhibitors

Nov. 7, 1997

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Hematologic
RSS

Fibrinogen receptor occupancy, antiplatelet activity and safety of lefradafiban

Lamifiban efficacy demonstrated in PARAGON trial

Preclinical and clinical profile of Searle's fibrinogen antagonist

TP-9201 covered by new U.S. patent

Fibrinogen antagonists from Merck & Co.

Spotlight on thrombin inhibitors

ReoPro cleared in U.S. for expanded labeling

Saruplase efficacy demonstrated in large patient study

PEG-hirudin compared to established antithrombotic agents

Akzo Nobel prepares two series of thrombin inhibitors

Today's news in brief

Today's news in brief

In muscular dystrophies, gene therapies race the clock

Bridgebio, with FDA approval, faces Pfizer in ATTR

Radiopharma Telix acquires FAP-targeting agents for bladder cancer

Hematologic RSS

Hematologic
RSS